A5004996430- Cannabis and Cannabinoid Research
- Homelessness and Social Issues
- Sleep and Wakefulness Research
- Sleep and related disorders
- Autism Spectrum Disorder Research
- Bipolar Disorder and Treatment
- Religion, Spirituality, and Psychology
- Infant Health and Development
- Prenatal Substance Exposure Effects
- Obsessive-Compulsive Spectrum Disorders
- Epilepsy research and treatment
- Helicobacter pylori-related gastroenterology studies
- Neuroscience of respiration and sleep
- Public Health and Nutrition
- Child Nutrition and Feeding Issues
- Parkinson's Disease Mechanisms and Treatments
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Pain Management and Placebo Effect
- Psychedelics and Drug Studies
- Food Security and Health in Diverse Populations
- Berberine and alkaloids research
- Inflammatory Bowel Disease
- Toxin Mechanisms and Immunotoxins
- Medicinal Plant Extracts Effects
- Child and Adolescent Psychosocial and Emotional Development
Ben-Gurion University of the Negev
2018-2023
Teva Pharmaceuticals (Israel)
2022
Soroka Medical Center
2019-2021
Wolfson Medical Center
2017
Tel Aviv University
2017
Tel Aviv Sourasky Medical Center
2017
Rabin Medical Center
2017
Abstract There has been a dramatic increase in the number of children diagnosed with autism spectrum disorders (ASD) worldwide. Recently anecdotal evidence possible therapeutic effects cannabis products emerged. The aim this study is to characterize epidemiology ASD patients receiving medical treatment and describe its safety efficacy. We analysed data prospectively collected as part program 188 treated between 2015 2017. majority was based on oil containing 30% CBD 1.5% THC. Symptoms...
Chronic pain may be treated by medical cannabis. Yet, there is scarce evidence to support the role of cannabis in treatment fibromyalgia. The aim study was investigate characteristics, safety, and effectiveness therapy for
The use of medical cannabis (MC) is controversial. Support for its benefits based on small clinical series.The aim this study was to report the results a standardized interview that retrospectively assessed effects MC symptoms Parkinson disease (PD) and adverse in patients treated at least 3 months.The survey used telephone interviews using structured questionnaire subjective global impressions change various parkinsonian yes/no questions effects.Forty-seven nondemented with PD (40 men)...
A complex motor disorder is a combination of various types abnormal movements that are associated with impaired quality life (QOL). Current therapeutic options limited. We studied the efficacy, safety, and tolerability medical cannabis in children disorder. This pilot study was approved by institutional ethics committee. Two products cannabidiol (CBD) enriched 5% oil formulation were compared: one 0.25% δ-9-tetrahydrocannabinol (THC) 20:1 group, other 0.83% THC 6:1 group. Patients aged 1 to...
Despite reports that medical cannabis improves symptoms in Crohn's disease [CD], controlled studies evaluating response are lacking. This study assessed the effect of cannabidiol [CBD]-rich oil for induction remission CD.In a double-blind, randomised, placebo-controlled, single-centre trial, patients received orally either containing160/40 mg/ml cannabidiol/tetrahydrocannabinol [CBD/THC] or placebo 8 weeks. Disease parameters, including CD activity index [CDAI], and simple endoscopic score...
Background Cannabis is often used by patients with ulcerative colitis, but controlled studies are few. We aimed to assess the effect of cannabis in improving clinical and inflammatory outcomes colitis patients. Methods In a double-blind, randomized, placebo-controlled trial, received either cigarettes containing 0.5 g dried flowers with80mgTetrahydrocannabinol (THC)or placebo for 8 weeks. Parameters disease including Lichtiger activity index, C reactive protein (CRP), calprotectin, Mayo...
Despite the absence of rigorous prospective studies, there has been an increase in use cannabis-based medicinal products. During study period, medical cannabis Israel was tightly regulated by national policy. Through a approximately 10,000 patients, we aimed to characterize patient population as well identify treatment adherence, safety, and effectiveness.In this prescribed effectiveness were assessed at 6 months. Treatment adherence proportion patients purchasing medication out total number...
Use of medical cannabis for improving symptoms inflammatory bowel disease is increasing. However, reports on long-term outcomes are lacking. This prospective, observational study assessed the effects licensed use among patients with disease.Dose and mode consumption, adverse events, other medications, were evaluated 127 using legalized cannabis. Blood count, albumin, C-reactive protein before, 1 month, at least year after therapy was initiated. Questionnaires activity, patient function,...
Almost 90% of patients with dementia suffer from some type neurobehavioral symptom, and there are no approved medications to address these symptoms.To evaluate the safety efficacy medical cannabis oil "Avidekel" for reduction behavioral disturbances among dementia.In this randomized, double-blind, single-cite, placebo-controlled trial conducted in Israel (ClinicalTrials.gov: NCT03328676), aged at least 60, a diagnosis major neurocognitive disorder associated were randomized 2:1 receive...
Objective: Tourette's syndrome (TS) is a neurodevelopmental disorder characterized by vocal and motor tics other comorbidities. Clinical recommendations for the use of medical cannabis are established, yet further guidance needed. The aim this study was to describe experience patients with TS cannabis. Materials Methods: were recruited from registry ("Tikun Olam" company). Questionnaires answered before after 6 months treatment. Patients divided into two groups: (A) who responded (B) did not...
Many patients with ulcerative colitis after ileoanal pouch anastomosis report improvement of pouchitis the use cannabis. Nine chronic used 1 g/d cannabis: 7 were male average age 51 ± 16 years. Average partial disease activity index 11 (range 8-17), 6 5-8), and 5 4-8); endoscopic subscores .3 2.3, 1.1, 4.4 0.9; bowel movements per day 14 8-20), 8 2-13), 10 13-8); quality life increased from 72 to 90 97 (P = 0.001) before cannabis treatment 8-12 52 weeks, respectively. No adverse events reported.
<h3>Background:</h3> Although chronic pain is a well established indication for medical cannabis therapy, there scarce evidence to support the role of in treatment fibromyalgia. <h3>Objectives:</h3> The aim study was investigate characteristics, safety and effectiveness therapy <h3>Methods:</h3> A prospective with 6 months follow-up period based on fibromyalgia patients who were willing answer questionnaire specialized clinic between 2015 2017. <h3>Results:</h3> Among 367 mean age 52.9±15.1,...